Orforglipron
Research Goal: Analyzing the efficacy of a small-molecule GLP-1RA for gastric emptying inhibition and satiety signaling via oral administration.
Route
Oral
Dose range
12 mg – 45 mg
Frequency
Once per day
Cycle length
Chronic administration for metabolic research
Overview
Research Goal: Analyzing the efficacy of a small-molecule GLP-1RA for gastric emptying inhibition and satiety signaling via oral administration.
Preparation: Administered as an oral tablet. No reconstitution or injection required.
Studied benefits
- A non-peptide, oral GLP-1 receptor agonist designed for weight management and type 2 diabetes
- Unlike injectable GLP-1s, it offers high bioavailability in pill form, leading to significant weight loss and improved glycemic control by suppressing appetite and slowing gastric emptying
Reported side effects
- Primarily gastrointestinal, including nausea, vomiting, and diarrhea, particularly during the initial dosing phase
- These effects typically diminish over time with consistent use
Protocol
Dosing Schedule (Oral)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Context
Lifestyle considerations
Follow a high-protein, balanced diet to preserve lean muscle mass while this non-peptide GLP-1 receptor agonist works to manage appetite and blood glucose levels. Incorporate regular physical activity to maximize metabolic expenditure and improve cardiovascular health markers during the weight-management protocol. Ensure 7–9 hours of quality sleep to regulate hunger hormones like ghrelin, which works in synergy with the compound’s satiety-promoting mechanism. Maintain optimal hydration and monitor for gastrointestinal side effects, utilizing smaller, more frequent meals if nausea or delayed gastric emptying occurs.
Evidence
Research summaries
Efficacy and safety of oral orforglipron in patients with type 2 diabetes
Findings: Drops blood sugar big time, sheds pounds (up to 10kg), easier pill over shots for diabetes control.
Orforglipron, a mouth-friendly GLP-1 mimic (not real peptide but acts like one), fights type 2 diabetes hunger hormone. Phase 2 trial: diabetes patients took escalating doses vs. placebo or shot rival. At 36-45mg, HbA1c (sugar average) plunged vs. others; weight fell 10kg max (placebo just 2kg). Like appetite brake plus fat burner. Mild nausea common but faded. Game-changer: daily pill matches injections sans needles, for steady energy sans sugar crashes. Helps overweight teens dodge family diabetes too.
Read the study ↗Orforglipron in type 2 diabetes mellitus and obesity
Findings: Weight loss up to 13kg, shrinks waist 8cm+, lowers blood pressure.
Review hit trials: orforglipron slashed HbA1c 2.1%, weight 10+kg, waist notably. Tops GLP-1s for slimming in meta-checks. Pressure eased sans diabetes even. Nausea/vomiting mild-higher doses, ramp slow. Oral ease beats shots for obesity fight, steady energy for active life. Like reset button on overeating cycle.
Read the study ↗Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Findings: 72-week weight drop superior placebo, consistent GLP-1 safety.
Phase 3 obese adults: 6-36mg orforglipron + diet/activity beat placebo on % weight loss. Gut-similar sides. Pill freedom for long-haul slimming, sustained pep.
Read the study ↗Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Findings: HbA1c down 1%+, manages early diabetes well.
Early diabetes trial: doses crushed placebo on sugar control. Oral win for new cases, prevents worsening.
Read the study ↗Identification
Chemistry
- cas
- 2212020-52-3 (free base)
- formula
- C₄₈H₄₈F₂N₁₀O₅
- molecular weight
- 882.97 g/mol (882.38 g/mol reported variant)
- source
- Synthetic; rationally designed through structure-based medicinal chemistry
- biosynthesis
- Non-ribosomal; chemically synthesized through multi-step organic synthesis
- type
- Complex bicyclic/polycyclic small molecule; non-peptide structure fundamentally distinct from GLP-1 peptide sequence
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks